|
|
Gene Symbol |
IL6ST |
|
Aliases |
CD130, CDW130, GP130, HIES4, IL-6RB, sGP130 |
|
Entrez Gene ID |
|
|
Gene Name |
Interleukin 6 signal transducer |
|
Chromosomal Location |
5q11.2 |
|
HGNC ID |
|
|
Summary |
The protein encoded by this gene is a signal transducer shared by many cytokines, including interleukin 6 (IL6), ciliary neurotrophic factor (CNTF), leukemia inhibitory factor (LIF), and oncostatin M (OSM). This protein functions as a part of the cytokine receptor complex. The activation of this protein is dependent upon the binding of cytokines to their receptors. vIL6, a protein related to IL6 and encoded by the Kaposi sarcoma-associated herpesvirus, can bypass the interleukin 6 receptor (IL6R) and directly activate this protein. Knockout studies in mice suggest that this gene plays a critical role in regulating myocyte apoptosis. Alternatively spliced transcript variants have been described. A related pseudogene has been identified on chromosome 17. [provided by RefSeq, May 2014]
|
|
e!Ensembl
Gene |
|
|
Transcript |
ENST00000381298, ENST00000651614, ENST00000503773, ENST00000502326, ENST00000381294, ENST00000381293, ENST00000381286, ENST00000522633, ENST00000381287, ENST00000336909, ENST00000396816 |
|
Protein |
ENSP00000370698, ENSP00000498224, ENSP00000426224, ENSP00000462158, ENSP00000370694, ENSP00000370693, ENSP00000370686, ENSP00000435399, ENSP00000370687, ENSP00000338799, ENSP00000463896
|
|
|
Gene Ontology (GO)
GO ID |
Ontology |
Function |
Evidence |
Reference |
GO:0002675 |
Biological process |
Positive regulation of acute inflammatory response |
IC |
8999038 |
GO:0002821 |
Biological process |
Positive regulation of adaptive immune response |
IC |
14764690 |
GO:0008284 |
Biological process |
Positive regulation of cell proliferation |
IBA |
21873635 |
GO:0008284 |
Biological process |
Positive regulation of cell proliferation |
IDA |
2261637 |
GO:0008284 |
Biological process |
Positive regulation of cell proliferation |
IGI |
8999038 |
GO:0010575 |
Biological process |
Positive regulation of vascular endothelial growth factor production |
TAS |
10744750 |
GO:0010613 |
Biological process |
Positive regulation of cardiac muscle hypertrophy |
TAS |
10744750 |
GO:0019221 |
Biological process |
Cytokine-mediated signaling pathway |
IDA |
2261637 |
GO:0034097 |
Biological process |
Response to cytokine |
IDA |
2261637, 8999038 |
GO:0038165 |
Biological process |
Oncostatin-M-mediated signaling pathway |
IMP |
8999038 |
GO:0042102 |
Biological process |
Positive regulation of T cell proliferation |
IBA |
21873635 |
GO:0042102 |
Biological process |
Positive regulation of T cell proliferation |
IMP |
14764690 |
GO:0042531 |
Biological process |
Positive regulation of tyrosine phosphorylation of STAT protein |
IBA |
21873635 |
GO:0042531 |
Biological process |
Positive regulation of tyrosine phosphorylation of STAT protein |
IMP |
14764690 |
GO:0043066 |
Biological process |
Negative regulation of apoptotic process |
TAS |
17530315 |
GO:0045669 |
Biological process |
Positive regulation of osteoblast differentiation |
IMP |
12372336 |
GO:0048861 |
Biological process |
Leukemia inhibitory factor signaling pathway |
IDA |
8999038, 12643274 |
GO:0070102 |
Biological process |
Interleukin-6-mediated signaling pathway |
IMP |
2261637, 12643274 |
GO:0070106 |
Biological process |
Interleukin-27-mediated signaling pathway |
IMP |
14764690 |
GO:0070120 |
Biological process |
Ciliary neurotrophic factor-mediated signaling pathway |
IDA |
12643274 |
GO:0005896 |
Cellular component |
Interleukin-6 receptor complex |
IBA |
21873635 |
GO:0005896 |
Cellular component |
Interleukin-6 receptor complex |
IDA |
2261637, 12643274, 12829785 |
GO:0005900 |
Cellular component |
Oncostatin-M receptor complex |
IBA |
21873635 |
GO:0005900 |
Cellular component |
Oncostatin-M receptor complex |
IDA |
8999038 |
GO:0009897 |
Cellular component |
External side of plasma membrane |
IBA |
21873635 |
GO:0016020 |
Cellular component |
Membrane |
HDA |
19946888 |
GO:0043235 |
Cellular component |
Receptor complex |
IBA |
21873635 |
GO:0070062 |
Cellular component |
Extracellular exosome |
HDA |
23533145 |
GO:0070110 |
Cellular component |
Ciliary neurotrophic factor receptor complex |
IBA |
21873635 |
GO:0070110 |
Cellular component |
Ciliary neurotrophic factor receptor complex |
IDA |
12707266 |
GO:0004896 |
Molecular function |
Cytokine receptor activity |
IBA |
21873635 |
GO:0004897 |
Molecular function |
Ciliary neurotrophic factor receptor activity |
IDA |
12643274 |
GO:0004915 |
Molecular function |
Interleukin-6 receptor activity |
IBA |
21873635 |
GO:0004915 |
Molecular function |
Interleukin-6 receptor activity |
IDA |
2261637, 12643274 |
GO:0004923 |
Molecular function |
Leukemia inhibitory factor receptor activity |
IBA |
21873635 |
GO:0004923 |
Molecular function |
Leukemia inhibitory factor receptor activity |
IDA |
8999038, 12643274 |
GO:0004924 |
Molecular function |
Oncostatin-M receptor activity |
IBA |
21873635 |
GO:0004924 |
Molecular function |
Oncostatin-M receptor activity |
IDA |
8999038 |
GO:0005127 |
Molecular function |
Ciliary neurotrophic factor receptor binding |
IBA |
21873635 |
GO:0005127 |
Molecular function |
Ciliary neurotrophic factor receptor binding |
IPI |
12707266 |
GO:0005138 |
Molecular function |
Interleukin-6 receptor binding |
IBA |
21873635 |
GO:0005138 |
Molecular function |
Interleukin-6 receptor binding |
IPI |
12829785 |
GO:0005515 |
Molecular function |
Protein binding |
IPI |
8662591, 8999038, 10982829, 11238858, 14527405, 16051226, 18775332, 24407287, 24501689 |
GO:0019838 |
Molecular function |
Growth factor binding |
IPI |
8999038 |
GO:0019838 |
Molecular function |
Growth factor binding |
IPI |
8999038 |
GO:0019955 |
Molecular function |
Cytokine binding |
IBA |
21873635 |
GO:0019981 |
Molecular function |
Interleukin-6 binding |
IBA |
21873635 |
GO:0019981 |
Molecular function |
Interleukin-6 binding |
IPI |
12829785 |
GO:0042802 |
Molecular function |
Identical protein binding |
IPI |
24501689 |
GO:0042803 |
Molecular function |
Protein homodimerization activity |
TAS |
8390097 |
GO:0045509 |
Molecular function |
Interleukin-27 receptor activity |
IC |
14764690 |
|
Protein Information |
|
Protein Name |
Interleukin-6 receptor subunit beta, CD130 antigen, IL-6 receptor subunit beta, IL-6R subunit beta, gp130 of the rheumatoid arthritis antigenic peptide-bearing soluble form, gp130, oncostatin M receptor, interleukin receptor beta chain, membrane glycoprotein 130, membrane glycoprotein gp130, oncostatin-M receptor subunit alpha |
|
Function |
Signal-transducing molecule. The receptor systems for IL6, LIF, OSM, CNTF, IL11, CTF1 and BSF3 can utilize IL6ST for initiating signal transmission. Binding of IL6 to IL6R induces IL6ST homodimerization and formation of a high-affinity receptor complex, which activates Janus kinases (PubMed:2261637). That causes phosphorylation of IL6ST tyrosine residues which in turn activates STAT3 (PubMed:19915009, PubMed:23294003). Mediates signals which regulate immune response, hematopoiesis, pain control and bone metabolism (By similarity). Has a role in embryonic development (By similarity). Does not bind IL6 (PubMed:2261637). Essential for survival of motor and sensory neurons and for differentiation of astrocytes (By similarity). Required for expression of TRPA1 in nociceptive neurons (By similarity). Required for the maintenance of PTH1R expression in the osteoblast lineage and for the stimulation of PTH-induced osteoblast differentiation (By similarity). Required for normal trabecular bone mass and cortical bone composition (By similarity). |
|
|
UniProt |
|
|
PDB |
|
|
|
|
Interactions |
| |
STRING |
MINT |
IntAct |
ENSP00000334145 |
|
P13726 |
|
| |
View interactions
|
|
| |
Associated Diseases
Disease group | Disease Name | References |
Cardiovascular Diseases |
Myocardial Ischemia |
|
Endocrine System Diseases |
PCOS |
|
Immune System Diseases |
Rheumatoid Arthritis |
|
Neoplasms |
Prostate cancer |
|
Carcinoma |
|
Ovarian Cancer |
|
Colorectal Cancer |
|
Anaplastic Carcinoma |
|
Nervous System Diseases |
Middle Cerebral Artery Syndrome |
|
Cerebral Artery Infarction |
|
Cerebral Thrombosis |
|
Brain Infarction |
|
Nutritional and Metabolic Diseases |
Gluocose Intolerance |
|
Respiratory Tract Diseases |
Pneumonia |
|
|
References |
|
|
Nikolajuk Agnieszka, Kowalska Irina, Karczewska-Kupczewska Monika, Adamska Agnieszka, Otziomek Elzbieta, Wolczynski Slawomir, Kinalska Ida, Gorska Maria, Straczkowski Marek |
Department of Endocrinology, Diabetology, and Internal Medicine, Medical University of Bialystok, Bialystok, Poland. |
Diabetes. 2010 Apr;59(4):1026-9. doi: 10.2337/db09-1316. Epub 2010 Jan 26. |
Abstract
OBJECTIVE: Insulin resistance might play a role in the pathogenesis of polycystic ovarian syndrome (PCOS). The family of glycoprotein 130 (gp130) cytokines could influence insulin action. One of these cytokines is interleukin (IL)-6, which exerts a short-term insulin-sensitizing effect, whereas in a long-term period, it might induce insulin resistance. Some other gp130 activators are supposed to have beneficial metabolic effects. Gp130 is present in the circulation in the soluble form (sgp130), which inhibits intracellular gp130 signaling. The aim of the present study was to estimate the relation between sgp130 and insulin sensitivity in women with PCOS. RESEARCH DESIGN AND METHODS: We studied 78 women with PCOS (35 lean and 43 obese) and 34 healthy women (18 lean and 16 obese). The euglycemic-hyperinsulinemic clamp and the measurements of serum sgp130, IL-6, soluble IL-6 receptor (sIL-6R), and sex hormones were performed. RESULTS: Both obesity and PCOS were characterized by an increased sgp130 (P < 0.0001 and P = 0.0002, respectively). sIL-6R concentration was lower (P = 0.0036) in women with PCOS independently of obesity. Serum sgp130 was negatively correlated with insulin sensitivity when control and PCOS women were analyzed together (r = -0.36, P < 0.0001) and in the PCOS subjects separately (r = -0.34, P = 0.002). In multiple regression analysis, this correlation was significant after adjustment for BMI, waist, percent of body fat, postload glucose and insulin, triglycerides, and high-sensitive C-reactive protein. CONCLUSIONS: Serum sgp130 is inversely and independently associated with insulin sensitivity in women with PCOS. An increased serum sgp130 in obesity and PCOS suggests an inhibition of intracellular gp130 signaling in insulin-resistant conditions. |
|
|
|
|
| © 2019, Biomedical Informatics Centre, NIRRH |
National Institute for Research in Reproductive Health, Jehangir Merwanji Street, Parel, Mumbai-400 012
Tel: 91-22-24192104, Fax No: 91-22-24139412
|